RecruitingPhase 1NCT05544019
Study of SGR-1505 in Mature B-Cell Neoplasms
Studying ALK-positive large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Schrödinger, Inc.
- Principal Investigator
- Frank G Basile, M.D., MDSchrodinger Inc.
- Intervention
- SGR-1505(drug)
- Enrollment
- 98 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2027
Study locations (30)
- Banner Health - MD Anderson Cancer Center, Gilbert, Arizona, United States
- Christiana Care Hospital - Helen F Graham Cancer Center, Newark, Delaware, United States
- Napa Research, Pompano Beach, Florida, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Regional Cancer Care Associates, Hackensack, New Jersey, United States
- Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
- Weill Cornell, New York, New York, United States
- Montefiore Medical Center, The Bronx, New York, United States
- Duke University, Durham, North Carolina, United States
- Gabrail Cancer & Research Center, Canton, Ohio, United States
- The Ohio State University - The James Cancer Hospital, Columbus, Ohio, United States
- Oregon Health and Science University - Knight Cancer Institute, Portland, Oregon, United States
- Rhode Island Hospital, Providence, Rhode Island, United States
- University of Texas Southwestern, Dallas, Texas, United States
- Fred Hutchinson Cancer Center, Seattle, Washington, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05544019 on ClinicalTrials.govOther trials for ALK-positive large B-cell lymphoma
Additional recruiting or active studies for the same condition.